Status of safety pharmacology in the pharmaceutical industry-1995.
- Published in:
- Drug Development Research, 1995, v. 35, n. 3, p. 166, doi. 10.1002/ddr.430350310
- By:
- Publication type:
- Article
Works matching IS 02724391 AND DT 1995 AND VI 35 AND IP 3
Results: 16
1
2
Inhibition of pyruvate dehydrogenase kinase by halogenated acetophenones.
- Published in:
- Drug Development Research, 1995, v. 35, n. 3, p. 130, doi. 10.1002/ddr.430350303
- By:
- Publication type:
- Article
3
Psychopharmacology: The fourth generation of progress. F. E. Bloom, D. J. Kupfer, eds., Raven Press, Ltd., New York, 1995, xlii + 2,002 pages, $175.
- Published in:
- Drug Development Research, 1995, v. 35, n. 3, p. 185, doi. 10.1002/ddr.430350314
- By:
- Publication type:
- Article
4
Clinical and regulatory perspectives on general/safety pharmacology tests: Results of a pharmaceutical industry survey.
- Published in:
- Drug Development Research, 1995, v. 35, n. 3, p. 150, doi. 10.1002/ddr.430350307
- By:
- Publication type:
- Article
5
Adenosine A<sub>1</sub> receptors in rat brain synaptosomes: Transductional mechanisms, effects on glutamate release, and preservation after metabolic inhibition.
- Published in:
- Drug Development Research, 1995, v. 35, n. 3, p. 119, doi. 10.1002/ddr.430350302
- By:
- Publication type:
- Article
6
Hypertension: Pathophysiology, diagnosis, and management. J. H. Laragh, B. M. Brenner, eds., Raven Press, Ltd., New York, 1994, 3,311 pages, $345.
- Published in:
- Drug Development Research, 1995, v. 35, n. 3, p. 183, doi. 10.1002/ddr.430350313
- By:
- Publication type:
- Article
7
Good laboratory practices and other regulatory issues: A European view.
- Published in:
- Drug Development Research, 1995, v. 35, n. 3, p. 145, doi. 10.1002/ddr.430350306
- By:
- Publication type:
- Article
8
Masthead.
- Published in:
- Drug Development Research, 1995, v. 35, n. 3, p. fmi, doi. 10.1002/ddr.430350301
- Publication type:
- Article
9
Safety pharmacology program for pharmaceuticals.
- Published in:
- Drug Development Research, 1995, v. 35, n. 3, p. 179, doi. 10.1002/ddr.430350312
- By:
- Publication type:
- Article
10
General pharmacology/safety pharmacology: Customers, biologics, and glps.
- Published in:
- Drug Development Research, 1995, v. 35, n. 3, p. 142, doi. 10.1002/ddr.430350305
- By:
- Publication type:
- Article
11
Announcement.
- Published in:
- Drug Development Research, 1995, v. 35, n. 3, p. 190, doi. 10.1002/ddr.430350316
- Publication type:
- Article
12
Good laboratory practices and other regulatory issues: A regulatory affairs view.
- Published in:
- Drug Development Research, 1995, v. 35, n. 3, p. 161, doi. 10.1002/ddr.430350309
- By:
- Publication type:
- Article
13
Pharmacological testing of recombinant human erythropoietin: Implications for other biotechnology products.
- Published in:
- Drug Development Research, 1995, v. 35, n. 3, p. 173, doi. 10.1002/ddr.430350311
- By:
- Publication type:
- Article
14
Esterification improves antiarthritic effectiveness of lupeol.
- Published in:
- Drug Development Research, 1995, v. 35, n. 3, p. 137, doi. 10.1002/ddr.430350304
- By:
- Publication type:
- Article
15
Prostaglandins and related compounds: Ninth International Conference, Florence, Italy (Advances in Prostaglandin, Thromboxane, and Leukotriene Research Vol. 23). B. Samuelsson, P. W. Ramwell, R. Paoletti, G. Folco, E. Granstrom, S. Nicosia, eds., Raven Press, Ltd., New York, 1995, $95.00
- Published in:
- Drug Development Research, 1995, v. 35, n. 3, p. 189, doi. 10.1002/ddr.430350315
- By:
- Publication type:
- Article
16
An FDA perspective on general pharmacology studies to determine activity and safety.
- Published in:
- Drug Development Research, 1995, v. 35, n. 3, p. 158, doi. 10.1002/ddr.430350308
- By:
- Publication type:
- Article